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Background: To coordinate and align the content for
registration of cholesteatoma care.
Methods: Systematic Delphi consensus procedure, consisting
three rounds: two written sessions followed by a face-to-face
meeting. Before this procedure, input on important patient
outcomes was obtained. Consensus was defined as at least
80% agreement by participants. Hundred-thirty-six adult
patients who had undergone cholesteatoma surgery and
all ENT surgeons of the Dutch ENT Society were invited. The
consensus rounds were attended by ENT surgeons with
cholesteatoma surgery experience. Feasibility and acceptability
of outcome measures and reporting agreements were assessed
in round 1 by 150 ENT surgeons. In round 2 definitions were
narrowed and context information to interpret outcome mea-
sure were questioned. In round 3, the results, amendments,
and the open-ended points were discussed to reach agreement.
Results: Most important outcome measures are: 1) the presence
or absence of a cholesteatoma in the first 5 years after surgical
removal of cholesteatoma, 2) hearing level after surgical
removal of cholesteatoma, and 3) the documented assessment
of patient’s complaints with a validated patient reported
outcome measures questionnaire (PROM). Furthermore, consen-
sus was reached on the registration of cholesteatoma type
(residual/recurrent), localization of cholesteatoma, and reporting
of the presence of cholesteatoma in the follow-up.
Conclusion: Consensus was reached on the content and
method of registration of cholesteatoma care based on
patient’s and ENT surgeons input. Three outcome measures
were defined. National agreements on the method and
content of registration will facilitate monitoring and feedback
to the ENT surgeon about the cholesteatoma care.
Key Words: Cholesteatoma—Clinical practice guideline—
Consensus—Health policy—Middle ear—Otology.
Otol Neurotol 41:1094–1101, 2020.
Despite the low incidence of cholesteatoma (1), every
ENT practice will see patients with this condition because
of its recurrent nature. In the Netherlands, 1,000 to 3,000
cholesteatoma-related operations are performed every
year. Although cholesteatoma occurs at all ages and all
over the world (2), there are no national or international
guidelines for the registration, treatment, or follow-up of
cholesteatoma. However, the Dutch ENT Society has now
taken the initiative to develop a cholesteatoma guideline
for registration and follow-up of cholesteatoma patients.
Part of such guideline is a plan to monitor the actual
performance. That is why simultaneously steps have been
taken in setting up a national otology quality registry.
A quality registry generates information on care (struc-
ture, process, and outcomes) based on the perspectives of
both health providers and their patients on quality of care
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(3). This information, often expressed as quality indicators,
can be used to obtain feedback on the results of the care
provided by the individual participating ENT surgeons in
relation to a benchmark. This comparison stimulates
improvement as goals can be set based on best practices (4).
The definition, classifications, pathology, and treat-
ment are an ongoing discussion in international scientific
literature but also to improve uniform registration (5–8).
Recent published international classifications are
STAMCO, ChOLE, and SAMEO-ATO (7–9).
This project aims to identify suitable outcome mea-
sures for cholesteatoma care from both the patient’s and
the ENT surgeon’s perspective. Describing outcome
measures requires uniform definitions and terminology
as well as registration agreements, which is why the study
will also sharpen definitions. Moreover, it is important
that data can be interpreted correctly, so that outcome
differences may be related to differences in pathology,
surgery, or other relevant (context) parameters.
Tobeable to register cholesteatomacare in theNetherlands
in a better and uniform manner, an attempt has been made to
find answers to the following research questions:
1) What are suitable outcome measures for choles-
teatoma care?
2) What context information is required for the
selected outcome measures?
3) Which terminology used requires further standard-
ization of definitions?
MATERIALS AND METHODS
A Delphi consensus procedure was performed to decide on
the data for monitoring cholesteatoma care (10–12). This
systematic method consisted of two written sessions (rounds
1 and 2) followed by a face-to-face meeting (round 3). The
preliminary set of information was based on input from a
professional expert team (authors) as well as a patient survey
on important outcomes on cholesteatoma care. The potential
participants approached for the Delphi procedure were ENT
surgeons who, at the time, were members of the Dutch ENT
Society with experience in cholesteatoma surgery.
For all the consensus rounds in the Delphi study, consensus
was defined as at least 80% of the ENT surgeons reaching
agreement, which is a relatively strict cut-off point (13,14). All
digital surveys were sent out using Castor-EDC (Amsterdam,
the Netherlands). ENT surgeons had 2 weeks to complete the
survey with a reminder after 1 week. After each round, ENT
surgeons were asked to provide additional relevant information,
and at the end of each round the results were shared online. The
entire Delphi process (shown in Fig. 1) was completed within
6 months (November 2018–May 2019) (15).
Preparations
First of all, an expert team was appointed: three ENT
surgeons from university hospitals, three ENT surgeons from
non-university hospitals, a Ph.D. researcher, a Dutch ENT
society board member, a scientific researcher specialized in
developing and selecting quality indicators, and a Professor of
Auditory Functioning and Participation (authors, n¼ 9).
To obtain a better understanding of outcome measures that are
important for patients, a list of the most frequently reported
symptoms (both pre- and postoperative) was drawn up from the
literature (16–19). This information was combined with
the information on overall patients’ symptoms taken from the
national Dutch Cholesteatoma Data study (DCD) (trial 80-
83700-98-16504). The input of literature and this cohort was
used to develop a patient survey on relevant outcome and process
measures in cholesteatoma care from the patient’s perspective
(see table, Supplemental Digital Content 1, http://links.lww.com/
MAO/B38, which demonstrates patient survey).
Questions Asked Were
1) Which symptoms should be included in the patient
record (both before and after surgery);
2) Should these symptoms be discussed by the ENT sur-
geon in a particular order;
3) What determines the success of cholesteatoma treatment
for the patient;
4) What other factors, according to the patient, contribute
to the quality of care?
For each question, the patients were able to fill in several
answers and, if necessary, to give additional information. A total
of 136 patients from DCD were asked to answer these questions
(METc approval VUmc, no. 2016.523). The participants were
adult patients who had undergone surgery for cholesteatoma
removal. These patients either had primary, recurrent, or residual
cholesteatoma and the survey was sent out during their first year
of follow-up after their (last) cholesteatoma surgery. Some of the
patients had already several surgeries and multiple Magnetic
resonance imaging or computed tomography (CT) scans in the
past 4 years. Others just had the first surgery and their first MRI.
This group of 136 patients had different complaints, hearing
levels, and impact. Within this cohort of adult patients, age, social
status, profession, and sex were well distributed.
After anonymization, the survey was analyzed using descrip-
tive statistics. The percentages for each question were calcu-
lated for each answer category. The expert team was then given
the top answers per question to enable them to draw up the list of
possible outcome measures in round 1.
Round 1
All 556 ENT surgeons of the Dutch ENT society were invited by
email to participate in the survey of round 1. The aim of this round
was to define a limited set of outcome measures and to determine
the required reporting on pathology, surgery, and aftercare. The
participants were asked whether the availability of this information
contributes to the quality of care. And asked whether the requested
information is already in the electronic medical record (EMR), or
whether the ENT surgeon is willing to register this information in
the EMR. In addition, two questions were asked about current
follow-up (no follow-up performed or the use of CT scan). These
questions were asked in preparation for round 2.
Round 2
For the second round, ENT surgeons who had participated in
the first round and also had experience with cholesteatoma
surgery (150) were invited. Based on the results of the first round,
consensus was sought on the contextual information required to
interpret the proposed outcome and process measures properly.
Round 3
All participants who responded in rounds 1 or 2 received an
invitation to attend the final joint meeting. The purpose of the
joint meeting was to present the results of the previous rounds
and to discuss them jointly. Issues from round 2 with a consensus
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percentage between 55 and 80% were presented to the partic-
ipants again to clarify any ambiguities and were reassessed with
the help of a digital voting system. In addition, five groups were
formed to discuss and select: the use of a certain classification
(ChOLE or STAMCO) to register the cholesteatoma (7,8), the
classification for surgery type (SAMEO-ATO) (9) and about
validated patient reported outcome questionnaires (PROM) to
uniformly register the patients’ symptoms. These were the
COMQ-12 and OQUA (20,21). This third round was led by an
independent process consultant with experience in consensus
discussions and setting up care registries.
RESULTS
Patient Survey
Ninety-six out of 136 surveys were completed (70.5%);
no incomplete surveys were returned. Both before and
after the cholesteatoma operation, the most frequently
reported symptom is ‘‘hearing loss.’’ In addition, the
two other most frequently reported symptoms are preop-
erative ‘‘otorrhea (ear discharge)’’ and ‘‘feeling of pres-
sure in the ear.’’ Postoperative symptoms are ‘‘tinnitus’’
and ‘‘feeling of pressure in the ear.’’ The survey also
showed that the factors determining whether surgery is
perceived as being successful by patients are ‘‘no recur-
rence of the cholesteatoma,’’ ‘‘improved hearing,’’ and
‘‘no complications.’’ The factors that patients considered
crucial in determining the quality of care are ‘‘communi-
cation with the physician,’’ ‘‘being able to discuss the fear
of recurrence of the cholesteatoma,’’ and ‘‘number of
visits to outpatient clinic’’ (see Table 1). From the patient’s
perspective, it is important to include this data for the
uniform registration of cholesteatoma care.
FIG. 1. Contents of Delphi procedure for cholesteatoma care.
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Round 1: ENT Surgeon Survey
Three outcome measures were drawn up based on the
patient survey results, the literature, and the discussion in
the expert team (Fig. 2). These outcome measures were
presented in round 1 next to the reporting on pathology,
diagnostics, surgery, and aftercare statements (see
Table 2).
This was first expressed in general terms, so that in the
next round, the statements for which agreement had been
reached, were specified further.
Of the 556 ENT surgeons, 192 completed the first
survey and 150 ENT surgeons indicated that they also
performed cholesteatoma surgery.
Table 2 shows that the proposed statements met the
consensus norm of 80%. The PROM raised questions, as
many surgeons do, or do not, use a PROM in choles-
teatoma care. Furthermore, 43% of the ENT surgeons
indicated that there may be situations in which no follow-
up is performed (i.e., no MRI or second look surgery)
after cholesteatoma surgery. 61% of the ENT surgeons
occasionally use a CT scan in the follow-up. Numerous
comments were made about the definitions and termi-
nology. The expert team took these comments into
account in the second round survey.
Round 2: ENT Surgeon Survey
In this round, consensus was sought on the context
information for the three selected outcome measures (see
Table 3).
A 70% consensus was reached on the definitions of
primary acquired, recurrent, and residual cholesteatoma.
In the definition the word ‘‘visible’’ was mistakenly used
instead of ‘‘poorly visible,’’ which was often com-
mented. The definition was modified and approved in
round 3. 87% of the respondents agreed with the pro-
posed way of reporting the presence of cholesteatoma
during the follow-up.
No consensus was reached on the use of the STAMCO
or ChOLE classification for the pathology and the
SAMEO-ATO classification for the surgical procedures.
However, the ENT surgeons did agree on the appropriate
intervals for MRI in the follow-up. The answers indicate
that 82% of ENT surgeons consider it desirable to perform
at least two MRIs in the first 5 years and 73% propose to
perform an additional MRI in the second or third year after
surgical removal. There was no consensus on MRI moni-
toring after these first 5 postoperative years.
The comments made in survey 2 showed that some
questions were not entirely clear, which meant that not all
respondents were able to answer these questions in the
same way. Many comments pertained to the third out-
come measure, the PROM. This was discussed during the
joint meeting.
Round 3: Joint Meeting
A total of 36 ENT surgeons from 25 different hospitals
were present at the joint meeting, including five members
of the expert team. The expert team members refrained
from voting, because of involvement in the development
of certain classification that were voted on during the
joint meeting and prevent bias due to preferences. The
results of rounds 1 and 2 were presented. Statements with
a score between 55 and 80% were further explained,
discussed, and reassessed. The definitions of the types of
acquired cholesteatoma were jointly corrected and
approved. Figure 3 shows the agreed definitions.
Next to this, it was decided in the meeting to add the
type of cholesteatoma to the context information for the
1st outcome measure (cholesteatoma presence) (96%).
And it was decided that a preoperative audiogram should
be performed no more than 6 months before the surgery
(83%).
TABLE 1. Patient survey: ear problems before/after surgery,
success factors, and cholesteatoma care quality, (n¼ 96)
n %
Ear problems before cholesteatoma surgery
Hearing loss 78 81%
Otorrhea (ear discharge) 50 52%
Feeling of pressure in ear 47 49%
Ear problems after cholesteatoma surgery
Hearing loss 63 66%
Tinnitus 45 47%
Feeling of pressure in ear 43 45%
Success factors
No recurrence of the cholesteatoma 70 73%
Improved hearing 51 53%
No complications 48 50%
Quality of cholesteatoma care
Communication with physician 75 78%
Being able to discuss the fear of
recurrence of the cholesteatoma
28 29%
Number of visits to outpatient clinic 23 24%
FIG. 2. Defined outcome measures.
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The classifications and PROMs were discussed inten-
sively in the meeting.
Classifications
The discussion showed that selecting a classification is
not most important, but rather the information provided
in the operative report. If the operative report contains all
matters from the existing classifications, then this should
be enough information for registration.
PROMs
The ENT surgeons were unable to decide between the
two validated questionnaires identifying the patients’
problems (OQUA or COMQ-12). Various issues
emerged from the discussion of the questionnaires.
According to those present, a shorter questionnaire that
is presented more often is more likely to be completed
than a longer one. The OQUA is suitable for all types of
ear procedures, which could make things easier for a
practice than having a different questionnaire for each
type of procedure/pathology. It was decided to first
obtain more clarity on the choice of the PROM, before
identifying the context information needed.
DISCUSSION
The study was carried out to reach a consensus on
uniform registration of cholesteatoma care and is, as
such, the first documented consensus in this field (both
nationally and internationally). Three rounds of the Del-
phi method were used to systematically involve ENT
surgeons to achieve registration agreements. The study
provides a clear picture of the outcome measures in the
treatment of primary acquired and other cholesteatomas
that can possibly be used as quality indicators. These are:
1) the presence/absence of a cholesteatoma in the first
5 years after surgical removal of cholesteatoma, 2)
hearing level after surgical removal of cholesteatoma,
and 3) the documented assessment of patient’s com-
plaints with a validated patient reported outcome mea-
sures questionnaire (PROM).
During the whole study, two of the three outcome
measures were adjusted. The first outcome measure did
initially not include a time frame. Because this outcome
measure can only be evaluated after a longer follow-up
period, it was decided by the expert team to add a fixed
time period. Various follow-up time frames were pro-
posed and a follow-up of 5 years was eventually agreed
upon. There is sufficient evidence that a long follow-up
of at least 5 years is useful after cholesteatoma surgery
(22) and ‘‘this five-year period may prevent the early
discharge of follow-up after cholesteatoma surgery.’’
Furthermore it is in line with the current majority for
MRI follow-up period and it is also comparable to cancer
survival rates (23). The second outcome measure repre-
sents the most important symptom for patients, namely,
the degree of hearing loss. For the last outcome measure,
it was decided to monitor the patients’ problems using a
validated questionnaire that was completed by the
patients (PROM). A PROM is the basis for uniform
registration of the subjective measure (24). In addition,
the definitions of cholesteatoma types and the method of






1 Reporting the type of cholesteatoma (primary, residual, recurrent) 96% 97%
Diagnosis
2 Mastoid CT prior to primary cholesteatoma surgery 99% 98%
3 Audiogram with bone conduction before cholesteatoma surgery 99% 99%
Surgery
4 Standardized reporting of the localization(s) of the cholesteatoma 89% 95%
5 Standardized reporting of the status of the ossicular chain 93% 97%




7 MRI diffusion imaging after cholesteatoma surgery 87% 97%
7a Do you use MRI diffusion? 91%
8 Audiogram with bone conduction after cholesteatoma surgery 99% 99%
Outcome measures
9 The presence/absence of a cholesteatoma in the first 5 years after surgical
removal of cholesteatoma
90% 94%
10 Hearing level after surgical removal of cholesteatoma 89% 96%
11 The documented assessment of patient’s complaints with a validated patient
reported outcome measures questionnaire (PROM)
80% 79%
Extra Yes No
12 Are there situations in which there is no follow-up at all (i.e., no MRI or
second look surgery) after cholesteatoma surgery?
43% 57%
13 Do you ever use a CT scan in the follow-up after cholesteatoma surgery? 60% 40%
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reporting the presence of cholesteatoma were established
which prevent ‘‘contamination’’ of the registration. The
definitions distilled from this study for the types of
cholesteatoma are more specific than those mentioned
in the consensus paper by Yung et al. (25).
To be able to judge the outcome measures properly, it
had to be decided which context information is impor-
tant. ENT surgeons need to relate their results to the case-
mix of patients, so that the outcome measures can be used
in a nuanced way. A total of three context items were
defined for the first outcome measure and four for the
second outcome measure. No further context items were
agreed upon for the third outcome. Ideally, a validated
questionnaire should include questions about the hearing,
which would then give a complete picture. However, the
use of a questionnaire or the systematic questioning of
patients regarding their symptoms does not yet appear to
be general practice. The national cholesteatoma study
and the literature (16,17) show that hearing loss with or
without otorrhea is the most important health concern. In
addition, to improve hearing, the cessation of otorrhea is
a determining factor for the success of surgery according
to patients. These success factors are also mentioned in
the studies of Lailach et al. (18) and Dornhoffer et al. (19),
TABLE 3. ENT surgeons survey 2: degree of consensus (in %) on the context information (n¼ 131)
1. The presence/absence of a cholesteatoma in the first 5 years after surgical removal of cholesteatoma
Consensus percentage
80
Type of surgery performed 85%
Localization/growth of cholesteatoma 84%
Number of years after primary surgery 80%
55–79
Complicated cholesteatoma cases (e.g., horizontal canal dehiscence or facial nerve paresis) 69%
Type of cholesteatoma during the procedure (primary, recurrent, residual, recurrent or residual from another hospital) 69%
Status of the ossicular chain 59%
Patient’s age at the time of primary surgery (in years) 57%
< 55
Status of the middle ear mucosa during the primary procedure (e.g., healthy / irritation) 27%
Other, namely 8%
None of the above 2%
2. Hearing level after surgical removal of cholesteatoma
Consensus percentage
80
Audiogram before surgery 95%
Audiogram after surgery 90%
Type of ossicular chain reconstruction performed 87%
Status of ossicular chain 85%
55–79
Type of surgery performed 73%
Date of last middle ear surgery to date of current audiogram 60%
Postoperative dry, wet or OME ear at time of audiogram 60%
<55
Type of cholesteatoma during procedure (primary, recurrent, residual) 41%
Other, namely 5%
None of the above 1%
3. The documented assessment of patient’s complaints with a validated patient reported outcome measures questionnaire (PROM)
Consensus percentage
55–79
Audiogram before surgery 72%
Type of surgery performed 70%
Audiogram after surgery 69%
Localization/growth of cholesteatoma 63%
Complicated cholesteatoma cases (e.g., horizontal canal dehiscence or facial nerve paresis) 63%
Patient’s age at the time of primary surgery (in yrs) 62%
Status of ossicular chain 60%
Type of ossicular chain reconstruction performed 60%
The documented assessment of patient’s complaints with a validated patient reported outcome measures questionnaire (PROM) ‘‘(continued).’’
<55
Type of cholesteatoma 47%
None of the above 8%
Other, namely 6%
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and are questioned items in both proposed PROMs. In
view of these three acknowledgments, it seems that the
structural request for information on patients’ problems
using a PROM, before and after surgery, is an essential part
of the quality monitoring.
The method used has the potential of systematically
achieving a nationwide consensus between ENT surgeons
(after input by patients and preparations by an expert
team). The use of two consecutive written rounds in the
Delphi method was highly conducive to the in-depth study.
Another advantage of this ‘‘bottom-up’’ method is that
input from the ENT surgeons was completely anonymous
and not hindered by the opinions of (inter)national experts.
Which meant that ‘‘having to follow the norm’’ and the
conviction that strong opinions are decisive could be
avoided (26,27). The expert team noticed, in accordance
with the literature (28), that both feedback and reminders
after each round increased participation. The joint meeting
in the last round reinforced the results for several reasons.
The meeting encouraged discussions, which helped clarify
the argumentation, and in turn led to clear agreements on
reporting, necessary for the implementation of the moni-
toring program aimed to improve the cholesteatoma care.
In the literature, it is suggested that consensus can be
reached in a joint meeting of at least seven persons (11).
This requirement was amply met with a large representa-
tive group of ENT surgeons for the joint meeting. The high
cut-off point for consensus (80%), increases the chance of
reproducibility of the research (29). Furthermore, we think
that this group of patients can be representative for the
adult cholesteatoma patient in a Western country, because
patients in different stages of the disease (primary, recur-
rent, or residual disease), with different complaints and
impact, different surgical approaches, and different social
and economic status are included. These patients were
included from a multicenter study of 16 participating
centers spread across the Netherlands and the distribution
of included patients between peripheral and university
medical centers was normal. Next to this, the DCD had
ethical permission to send out questionnaires to these
patients, whereas patient participation according to a
newly set-up international consortium for health outcomes
measurement framework would not have been feasible for
this study. Furthermore, all patients were questioned at the
same moment in time, but during different stages of
individual follow-up.
The study also had a number of limitations. The second
survey included additional information on both classifi-
cations and the validated questionnaires. However, the
information had to be read in a too short period (2 weeks)
and some statements were interpreted differently than
intended. Clearer formulation and longer time could pos-
sibly have prevented these misinterpretations. The expert
group was looking for the best classification for Dutch
ENT practice in line with international classifications.
However, consensus could not be reached. Combining
separate elements of these classifications seemed a viable
compromise but needs additional debate. Furthermore, it
was decided to include the symptoms and only the com-
plications caused by the cholesteatoma itself and not
FIG. 3. Definition acquired cholesteatoma and categories agreed upon for presence of cholesteatoma in follow-up.
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complications caused by the surgeon. This was a conscious
decision by the expert team, because there are only a few
national registries within the ENT field and the response
rate is often related to how ‘‘sensitive’’ the information is.
A next step would be to include the surgical complications.
This report will be presented to the Dutch ENT Society
to support the development of a Otologic Quality registry.
CONCLUSION
National consensus has been achieved on outcome
measures, definitions, and a uniform way of registering
cholesteatoma care by using a Delphi consensus method
with input from both patients and ENT surgeons. This
consensus likely contains many valuable elements for the
uniform registration of cholesteatoma care worldwide as
well as for the establishment of (inter)national otologic
quality registry to ensure and improve cholesteatoma
patient care.
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